Angiodynamic Inc(ANGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.79 | Insider Own | 11.52% | Shs Outstand | 42.4M | Perf Week | 2.75% |
| Market Cap | 0.52B | Forward P/E | - | EPS next Y | 61.55% | Insider Trans | -0.48% | Shs Float | 37.2M | Perf Month | -19.7% |
| Enterprise Value | 0.50B | PEG | - | EPS next Q | -0.07 | Inst Own | 91.22% | Short Float | 5.15% | Perf Quarter | -16.5% |
| Income | -0.03B | P/S | 1.6 | EPS this Y | -82.03% | Inst Trans | -1.84% | Short Ratio | 3 | Perf Half Y | 12.89% |
| Sales | 0.33B | P/B | 3.2 | EPS next 5Y | - | ROA | -12.98% | Short Interest | 1.92M | Perf YTD | -3.82% |
| Book/sh | 3.86 | P/C | 15.29 | EPS past 3/5Y | 12.67% -1.46% | ROE | -19.21% | 52W High | -24.19% ($16.29) | Perf Year | 1.9% |
| Cash/sh | 0.81 | P/FCF | - | Sales past 3/5Y | -1.86% 1.93% | ROIC | -19.05% | 52W Low | 31.52% ($9.39) | Perf 3Y | 94.18% |
| Dividend Est. | - | EV/EBITDA | 172.27 | EPS Y/Y TTM | -0.88% | Gross Margin | 52.34% | Volatility(W/M) | 3.48% 5.87% | Perf 5Y | -56.82% |
| Dividend TTM | - | EV/Sales | 1.52 | Sales Y/Y TTM | 8.2% | Oper. Margin | -6.01% | ATR (14) | 0.59 | Perf 10Y | -19.81% |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | EPS Q/Q | 36.22% | Profit Margin | -10.12% | RSI (14) | 43.08 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.4 | Sales Q/Q | 6.87% | SMA20 | 0.18% ($12.33) | Beta | 0.26 | Target Price | $18.33 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/10/8 | SMA50 | -13.39% ($14.26) | Rel Volume | 0.75 | Prev Close | $12.13 |
| Employees | 632 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 64.44% 0.5% | SMA200 | -0.94% ($12.47) | Avg Volume(3M) | 0.64M | Price | $12.35 |
| IPO | 2004/5/27 | Option/Short | Yes/Yes | Trades | 3526 | Volume | 476,210 | Change | 1.81% |
🩺 AngioDynamics (ANGO) is a US-based medical technology company specializing in the development of minimally invasive medical devices for the treatment of vascular disease and the removal of cancerous tumors. The company went public on the NASDAQ market in 2004 and provides precision treatment solutions to medical professionals worldwide in the areas of peripheral arterial occlusion treatment and tumor ablation surgery through its advanced technology platforms, NanoKnife and IsoLoc (Orion).
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
ANGO has a sound balance sheet but weak earning power
Of every $100 in sales, $6.01 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -82.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $160. Peers typically go for $273.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -56.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 91.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
XHE State Street SPDR S&P Health Care Equipment ETF <0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
KOMP State Street SPDR S&P Kensho New Economies Composite ETF <0.01% 
IWC iShares Micro-Cap ETF <0.01% 
SMLV State Street SPDR US Small Cap Low Volatility Index ETF <0.01% It ranks #30 of 51 in the industry
Based on market cap of $519M.
FAQ
What kind of company is ANGO?
ANGO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of ANGO?
The market cap of ANGO is approximately $519M, ranking 3,127 within its sector.
What is the 52-week high and low for ANGO?
ANGO has recorded a 52-week high of $16.29 and a low of $9.39.
